Halozyme Therapeutics reported $476.09M in Current Liabilities for its fiscal quarter ending in September of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 332.22M 29.22M Sep/2026
Agios Pharmaceuticals USD 77.59M 7.37M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amarin USD 175.14M 10.94M Sep/2026
Amgen USD 23.23B 2.27B Sep/2026
Baxter International USD 3.81B 218M Sep/2026
Cara Therapeutics USD 8.08M 3.18M Sep/2026
Cytokinetics USD 353.42M 171.99M Sep/2026
DBV Technologies USD 58.5M 4.2M Sep/2026
Eli Lilly USD 47B 745M Sep/2026
Halozyme Therapeutics USD 476.09M 131.65M Sep/2026
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 435.29M 119.65M Sep/2026
MannKind USD 108.52M 34.37M Sep/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Pfizer USD 31.73B 920M Sep/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
United Therapeutics USD 624.3M 16.5M Sep/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025